Asset
Cenopodlin
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02812875 | phase1 | completed | 2016-05-01 | 2020-05-07 | Curis, Inc. | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas |
FDA applications (0)
This company has no applications containing this asset.